Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Molecular determinants of response to high-dose androgen therapy in prostate cancer.

Nyquist MD, Corella A, Mohamad O, Coleman I, Kaipainen A, Kuppers DA, Lucas JM, Paddison PJ, Plymate SR, Nelson PS, Mostaghel EA.

JCI Insight. 2019 Oct 3;4(19). pii: 129715. doi: 10.1172/jci.insight.129715.

2.

Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.

Kaipainen A, Zhang A, Gil da Costa RM, Lucas J, Marck B, Matsumoto AM, Morrissey C, True LD, Mostaghel EA, Nelson PS.

Prostate. 2019 Sep;79(13):1530-1542. doi: 10.1002/pros.23874. Epub 2019 Aug 2.

PMID:
31376206
3.

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C.

J Clin Invest. 2019 Jul 30;130:4492-4505. doi: 10.1172/JCI128212.

4.

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E.

Eur Urol. 2019 Jun 19. pii: S0302-2838(19)30449-X. doi: 10.1016/j.eururo.2019.05.042. [Epub ahead of print]

PMID:
31227306
5.

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18.

6.

Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.

Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, Mostaghel EA.

Prostate Cancer Prostatic Dis. 2019 Mar 19. doi: 10.1038/s41391-019-0141-6. [Epub ahead of print]

7.

Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.

Mostaghel EA.

Clin Cancer Res. 2019 Feb 15;25(4):1139-1141. doi: 10.1158/1078-0432.CCR-18-3410. Epub 2018 Dec 10.

PMID:
30530817
8.

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.

McKay RR, Werner L, Jacobus SJ, Jones A, Mostaghel EA, Marck BT, Choudhury AD, Pomerantz MM, Sweeney CJ, Slovin SF, Morris MJ, Kantoff PW, Taplin ME.

Cancer. 2019 Feb 15;125(4):524-532. doi: 10.1002/cncr.31836. Epub 2018 Nov 14.

PMID:
30427533
9.

Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.

Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP.

Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21.

PMID:
30242112
10.

Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.

Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS.

Clin Cancer Res. 2019 Jan 1;25(1):426-439. doi: 10.1158/1078-0432.CCR-18-1431. Epub 2018 Sep 4.

PMID:
30181386
11.

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP.

Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19.

12.

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.

Allott EH, Masko EM, Freedland AR, Macias E, Pelton K, Solomon KR, Mostaghel EA, Thomas GV, Pizzo SV, Freeman MR, Freedland SJ.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):196-203. doi: 10.1038/s41391-018-0045-x. Epub 2018 May 23.

13.

DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.

Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.

Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6. No abstract available.

PMID:
29287968
14.

Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.

McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, Mostaghel EA, Kantoff PW, Nelson PS, Kibel AS, Taplin ME.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):364-372. doi: 10.1038/s41391-017-0009-6. Epub 2017 Dec 20.

15.

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA.

Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review.

16.

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TM.

Endocr Relat Cancer. 2017 Aug;24(8):393-404. doi: 10.1530/ERC-17-0107. Epub 2017 Jun 29.

17.

Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.

Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA.

Mol Cancer Res. 2017 May;15(5):521-531. doi: 10.1158/1541-7786.MCR-16-0315-T.

18.

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.

Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, Le Magnen C, Chester D, Mostaghel EA, Califano A, Rubin MA, Shen MM, Abate-Shen C.

Cancer Discov. 2017 Jul;7(7):736-749. doi: 10.1158/2159-8290.CD-16-1174. Epub 2017 Apr 14.

19.

Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB.

Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7.

20.

Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.

Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JM, Mostaghel EA, Barbieri CE, Mitrofanova A, Abate-Shen C.

Eur Urol. 2017 Oct;72(4):499-506. doi: 10.1016/j.eururo.2017.03.031. Epub 2017 Apr 4.

21.

Harnessing Solute Carrier Transporters for Precision Oncology.

Nyquist MD, Prasad B, Mostaghel EA.

Molecules. 2017 Mar 28;22(4). pii: E539. doi: 10.3390/molecules22040539. Review.

22.

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E.

Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3.

23.

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME.

Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.

24.

Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Mostaghel EA, Martin PS, Mongovin S, Frayo S, Zhang A, Edlefsen KL, Press OW, Gopal AK.

Exp Hematol. 2017 May;49:34-38.e2. doi: 10.1016/j.exphem.2017.01.001. Epub 2017 Jan 21.

25.

Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.

Lam HM, McMullin R, Nguyen HM, Coleman I, Gormley M, Gulati R, Brown LG, Holt SK, Li W, Ricci DS, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella RL, Corey E.

Clin Cancer Res. 2017 May 1;23(9):2301-2312. doi: 10.1158/1078-0432.CCR-16-2054. Epub 2016 Dec 19.

26.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.

Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.

27.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970.

28.

Role of OATP transporters in steroid uptake by prostate cancer cells in vivo.

Green SM, Kaipainen A, Bullock K, Zhang A, Lucas JM, Matson C, Banks WA, Mostaghel EA.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):20-27. doi: 10.1038/pcan.2016.42. Epub 2016 Sep 20.

29.

A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.

Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC.

Prostate. 2016 Oct;76(14):1303-11. doi: 10.1002/pros.23219. Epub 2016 Jun 21.

30.

Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.

Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH.

Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14.

31.

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C.

Clin Cancer Res. 2016 Jul 15;22(14):3672-82. doi: 10.1158/1078-0432.CCR-15-2309. Epub 2016 Mar 2.

32.

Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Zhang A, Zhang J, Plymate S, Mostaghel EA.

Horm Cancer. 2016 Apr;7(2):104-13. doi: 10.1007/s12672-016-0250-9. Epub 2016 Jan 21. Review.

33.

In Reply to Bhattacharyya et al.

Cho E, Mostaghel EA, Russell KJ, Liao JJ, Montgomery B.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):719-20. doi: 10.1016/j.ijrobp.2015.06.026. No abstract available.

PMID:
26461011
34.

UDP-glucuronosyltransferase Enzymes in Prostate Cancer Progression: Is Only Androgen Catabolism Involved?

Mostaghel EA, Zhang A, Plymate S.

Eur Urol. 2016 Apr;69(4):610-612. doi: 10.1016/j.eururo.2015.08.025. Epub 2015 Aug 28. No abstract available.

PMID:
26318705
35.

Integrative Clinical Genomics of Advanced Prostate Cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053. Epub 2015 Jul 16. No abstract available.

36.

Integrative clinical genomics of advanced prostate cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul 16;162(2):454.

37.

Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma.

Izard JP, Gore JL, Mostaghel EA, Wright JL, Yu EY.

Clin Genitourin Cancer. 2015 Aug;13(4):e253-e258. doi: 10.1016/j.clgc.2015.02.008. Epub 2015 Mar 5.

PMID:
25882979
38.

External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.

Cho E, Mostaghel EA, Russell KJ, Liao JJ, Konodi MA, Kurland BF, Marck BT, Matsumoto AM, Dalkin BL, Montgomery RB.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):236-43. doi: 10.1016/j.ijrobp.2015.01.020. Epub 2015 Mar 12.

39.

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS.

PLoS One. 2014 Oct 30;9(10):e111545. doi: 10.1371/journal.pone.0111545. eCollection 2014.

40.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.

J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.

41.

Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression.

Cho E, Montgomery RB, Mostaghel EA.

Endocrinology. 2014 Nov;155(11):4124-32. doi: 10.1210/en.2014-1337. Epub 2014 Aug 22. Review.

42.

Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.

Mostaghel EA.

Int J Biol Sci. 2014 Jun 3;10(6):602-13. doi: 10.7150/ijbs.8844. eCollection 2014. Review.

43.

Practical guide to the use of abiraterone in castration resistant prostate cancer.

Mostaghel EA, Lin DW.

Can J Urol. 2014 Apr;21(2 Supp 1):57-63. Review.

44.

Glucocorticoids and prostate cancer treatment: friend or foe?

Montgomery B, Cheng HH, Drechsler J, Mostaghel EA.

Asian J Androl. 2014 May-Jun;16(3):354-8. doi: 10.4103/1008-682X.125392. Review.

45.

Abiraterone in the treatment of metastatic castration-resistant prostate cancer.

Mostaghel EA.

Cancer Manag Res. 2014 Jan 28;6:39-51. doi: 10.2147/CMAR.S39318. eCollection 2014. Review.

46.

Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP.

Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21.

47.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

48.

Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.

Mostaghel EA, Plymate SR, Montgomery B.

Clin Cancer Res. 2014 Feb 15;20(4):791-8. doi: 10.1158/1078-0432.CCR-12-3601. Epub 2013 Dec 4.

49.

Steroid hormone synthetic pathways in prostate cancer.

Mostaghel EA.

Transl Androl Urol. 2013 Sep;2(3):212-227.

50.

Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.

Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W, True L, Vessella R, Montgomery B, Blair IA, Penning TM.

J Steroid Biochem Mol Biol. 2013 Nov;138:281-9. doi: 10.1016/j.jsbmb.2013.06.014. Epub 2013 Jul 10.

Supplemental Content

Loading ...
Support Center